- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001145
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome
The primary goal of this Phase I/II study is to assess the immune response and safety of recombinant human CD40 ligand (rhuCD40L) in patients with X-linked hyper IgM syndrome (XHIM). XHIM is a rare genetic disease caused by mutations in the gene encoding CD40 ligand. Individuals with this syndrome fail to make gamma immune globulin, frequently suffer from opportunistic infections, and are at an increased risk of developing cancer. Despite treatment with gamma globulin replacement therapy, the expected survival of patients with XHIM is less than 20 percent by the age of 25.
In a mouse model of this syndrome, treatment with man-made CD40 ligand protein protected the mouse from opportunistic infections, restored the mouse's ability to make gamma globulin, and improved survival. We want to determine if a similar approach can work in humans with XHIM. The study will be conducted at the Clinical Center of the National Institutes of Health in Bethesda, Maryland.
For most patients, rhuCD40L will be administered by injection under the skin over a period of six months and follow-up exams are required at 2-month intervals for an additional 6 months. During the study, patients will be maintained on intravenous gamma globulin, antibiotics to protect against opportunistic infection, and, if needed, growth factors to control neutropenia. The immune response to rhuCD40Lwill be measured by routine methods such as measuring a patient's ability to synthesize gamma globulin when challenged with immunizations to keyhole limpet hemocyanin (KLH) and Bacteriophage Phi-X 174 (Phi-X 174). Our long-term goal is to define a therapeutic regimen that will provide effective immunological reconstitution to patients with XHIM and improve their life expectancy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
All patients must have a diagnosis of X-linked hyper IgM syndrome confirmed either by molecular analysis of the CD40L gene or by flow cytometry analysis demonstrating the failure of CD40L expression on activated T cells, and/or clear X-linked inheritance (with multiple affected males) in association with defective CD40L expression.
Age greater than or equal to 4 years
Patient and or parent (for children under the age of 18) must be able to understand and sign informed consent.
Life expectancy of greater than 6 months.
Average ANC of greater than 250 cells/microL measured over 3 days during the week prior to planned administration of rhuCD40L.
EXCLUSION CRITERIA:
Serious ongoing opportunistic infection.
Use of immune-based therapies other than IVIG such as corticosteroids (doses of prednisone greater than 0.4 mg/kg/d for more than 4 weeks within the 6 months prior to enrolling in the study or any use of corticosteroids equivalent to greater than or equal to 5 mg of prednisone at the time of enrollment) or other immunomodulating drugs within 6 months prior to enrollment in the study.
Current use of other investigational drugs.
Chronic liver disease or any confounding medical illness that in the judgement of the investigators would pose added risk for study participants (e.g. cancer, severe allergies, chronic renal or pulmonary disease).
SGOT, SGPT greater than 2 times normal range; and creatinine greater than 2.0 times normal
ANC less than 250/microL; Platelets less than 50,000/microL; Hematocrit less than 25
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Publications and helpful links
General Publications
- Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today. 1993 Nov;14(11):559-64. doi: 10.1016/0167-5699(93)90188-Q.
- Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev. 1992;3(2):101-21.
- Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, Fu SM, Stamenkovic I, Geha RS. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2170-3. doi: 10.1073/pnas.90.6.2170.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Blood Protein Disorders
- Primary Immunodeficiency Diseases
- Dysgammaglobulinemia
- Immunoproliferative Disorders
- Hyper-IgM Immunodeficiency Syndrome
- Hyper-IgM Immunodeficiency Syndrome, Type 1
Other Study ID Numbers
- 000006
- 00-I-0006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunoproliferative Disorder
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedLymphoproliferative DisorderUnited States
-
Charite University, Berlin, GermanyTerminatedPost-transplantation Lymphoproliferative DisorderAustralia, France, Germany, Sweden
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Lymphoproliferative Disorder | Refractory Lymphoproliferative DisorderUnited States
-
Masonic Cancer Center, University of MinnesotaMillennium Pharmaceuticals, Inc.TerminatedLymphoproliferative DisorderUnited States
-
Timothy VoorheesRecruitingPolymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderUnited States
-
Invivoscribe, Inc.RecruitingB-Cell Lymphoproliferative DisorderUnited States, Germany, Japan
-
University of EdinburghUnknownLymphoproliferative DisorderUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLymphoproliferative DisorderCanada, United States, Australia, New Zealand
-
Deepa JagadeeshTerminatedPost-transplant Lymphoproliferative DisorderUnited States
-
Charite University, Berlin, GermanyCompletedPosttransplant Lymphoproliferative Disorder | PTLDAustralia, France, Germany, Sweden, Belgium, Italy, Poland
Clinical Trials on Bacteriophage
-
Southwest Regional Wound Care CenterCompleted
-
Tashkent Pediatric Medical InstituteActive, not recruiting
-
Institute of Immunology and Experimental Therapy...Unknown
-
BiomX, Inc.Active, not recruitingCystic Fibrosis | Chronic Pseudomonas Aeruginosa InfectionUnited States, Israel, Spain, Czechia, Netherlands
-
Centre Hospitalier Universitaire de NīmesPherecydes PharmaNot yet recruitingDiabetic Foot | Staphylococcal InfectionsFrance
-
Intralytix, Inc.Johns Hopkins University; Icahn School of Medicine at Mount SinaiRecruiting
-
University of South FloridaUnknownPrimary Immune Deficiency DiseasesUnited States
-
Queen Astrid Military HospitalCompletedBacterial Infections
-
Colorado State UniversityMetabiomics Corp; George Mason UniversityCompletedGastrointestinal Disorder, Functional
-
Adaptive Phage Therapeutics, Inc.United States Department of DefenseTerminatedUrinary Tract Infection BacterialUnited States